Sepsis
Conditions
Interventions
Control group:After conventional therapy (targeted antimicrobial therapy directed against the pathogen identified by microbiological testing), no further intervention is given.
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age >=18 years and =2); 3. The study participant or their guardian can fully understand the content of the informed consent for this trial and voluntarily sign the informed consent form; 4. Able to attend follow-up visits, undergo follow-up examinations, and provide specimens, including blood and stool samples on time.
Exclusion criteria
Exclusion criteria: 1. Patients in a moribund state or who die within 48 hours of enrollment; 2. Patients who have participated in other drug studies within the past 3 months; 3. Patients who have received FMT treatment in the past 12 months; patients during pregnancy and postpartum; patients with immune abnormalities; 4. Patients who have used probiotics, prebiotics, antibiotics, or other medications that may affect the gut microbiota within 3 months prior to treatment, or who plan to use such medications in the following 4 months; 5. Patients previously diagnosed with organic gastrointestinal diseases or severe gastrointestinal issues requiring immediate treatment, such as congenital megacolon, intestinal perforation, gastrointestinal bleeding, intestinal obstruction, intussusception, inflammatory bowel disease, celiac disease, perianal infections, or patients with a stoma; 6. Patients with other serious diseases that could affect the evaluation of this study, such as severe liver disease, severe immunodeficiency, heart disease, cerebrovascular disease, kidney disease, malignancy, and alcoholism; 7. Other patients deemed unsuitable for enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sequential Organ Failure Assessment;Length of ICU stay;28-day mortality rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological indicators;Metabolite characteristics;Proteomic characteristics;The changes in the richness of the intestinal flora after treatment;Procalcitonin; | — |
Countries
China
Contacts
Public ContactLi Jiabin
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed